{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:57:10Z","timestamp":1791928630119,"version":"4.3.4"},"reference-count":92,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n \n \n \n \n This guideline has been updated.<\/jats:bold>\n <\/jats:p>\n \n This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the\n online dynamic version<\/jats:ext-link>\n for the latest updates.\n <\/jats:p>\n <\/jats:boxed-text>\n <\/jats:p>\n <\/jats:sec>\n \n PURPOSE<\/jats:title>\n To provide guidance regarding the systemic treatment of patients with high-grade serous and\/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) experiencing recurrence.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Eight hundred nineteen publications were identified in the literature search. After applying the eligibility criteria, 147 publications of randomized controlled trials and systematic reviews comprising the entire body of evidence remained, forming the evidentiary basis, of which 36 directly informed the guideline recommendations.<\/jats:p>\n <\/jats:sec>\n \n RECOMMENDATIONS<\/jats:title>\n For patients with recurrent platinum-sensitive EOC, clinicians should offer platinum-based combination regimens, specifically pegylated liposomal doxorubicin (PLD) plus carboplatin, paclitaxel plus carboplatin, or gemcitabine plus carboplatin. Bevacizumab may be added to a platinum-based doublet followed by bevacizumab maintenance. For patients who are not candidates for platinum-based therapy, clinicians may utilize recommendations for first-line treatment of patients with relapsed platinum-resistant disease. For patients with platinum-resistant or platinum-refractory EOC high-grade disease and validated folate receptor alpha (FR\u03b1) expression, mirvetuximab soravtansine is strongly recommended. Other recommended systemic options for this population include PLD monotherapy, paclitaxel (once weekly or once every 3 weeks), bevacizumab in combination with chemotherapy, or the combination of relacorilant and nab-paclitaxel; gemcitabine monotherapy remains a conditional alternative. Regarding surgical interventions, there is currently insufficient evidence to recommend secondary cytoreduction or hyperthermic intraperitoneal chemotherapy. Clinicians may discuss secondary cytoreduction for platinum-sensitive recurrences where complete gross resection is highly achievable. Post-treatment monitoring and specialty survivorship care should be offered on a case-by-case basis, potentially including physical exams, biochemical testing, and imaging. There is insufficient data to recommend one combination versus another.<\/jats:p>\n \n Additional information is available on the\n ASCO Publications website<\/jats:ext-link>\n .\n <\/jats:p>\n \n Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the<\/jats:italic>\n \n ASCO Guidelines Methodology Manual<\/jats:italic>\n <\/jats:ext-link>\n .\n ASCO Living Guidelines follow the<\/jats:italic>\n \n ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines<\/jats:italic>\n <\/jats:ext-link>\n . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients.<\/jats:italic>\n <\/jats:p>\n \n \n Clinical Practice Guidelines and other guidance (\u201cGuidance\u201d) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in the\n Appendix<\/jats:xref>\n (online only) for more\n <\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1200\/jco-26-01591","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:59:08Z","timestamp":1783972748000},"page":"2725-2744","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0"],"prefix":"10.1200","volume":"44","author":[{"given":"Jamie L.","family":"Lesnock","sequence":"first","affiliation":[{"name":"UPMC Magee-Womens Hospital, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1834-0551","authenticated-orcid":false,"given":"Sarah","family":"Temin","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-2152","authenticated-orcid":false,"given":"Sara","family":"Bouberhan","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-1380","authenticated-orcid":false,"given":"Sarah F.","family":"Adams","sequence":"additional","affiliation":[{"name":"University of New Mexico, Albuquerque, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Barber","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley C.","family":"Burkett","sequence":"additional","affiliation":[{"name":"Alabama Gynecologic Oncology, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-5693","authenticated-orcid":false,"given":"Luis","family":"Corrales","sequence":"additional","affiliation":[{"name":"Centro de Investigacion y Manejo del Cancer (CIMCA), San Jos\u00e9, Costa Rica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7693-2694","authenticated-orcid":false,"given":"Katherine C.","family":"Fuh","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7388-0243","authenticated-orcid":false,"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Saitama Medical University International Medical Center, International University of Health and Welfare, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Hardesty","sequence":"additional","affiliation":[{"name":"Alaska Women's Cancer Care, Anchorage, AK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Lefkowits","sequence":"additional","affiliation":[{"name":"University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Richardson","sequence":"additional","affiliation":[{"name":"Black Cancer Collaborative, Inc, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-3805","authenticated-orcid":false,"given":"B. J.","family":"Rimel","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari L.","family":"Ring","sequence":"additional","affiliation":[{"name":"University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney P.","family":"Rocconi","sequence":"additional","affiliation":[{"name":"University of Mississippi Medical Center, Jackson, MS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunja J.","family":"Rungruang","sequence":"additional","affiliation":[{"name":"Medical College of Georgia at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-4291","authenticated-orcid":false,"given":"Jennifer M.","family":"Scalici","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel RL","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, et al: Cancer statistics, 2026. CA Cancer J Clin 76:e70043, 2026","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_8_3_2","volume-title":"National Institutes of Health \u2013 National Cancer Institute: SEER. Cancer Stat Facts: Ovarian Cancer","author":"National Cancer Institute (or Surveillance E, and End Results Program)","year":"2020","unstructured":"National Cancer Institute (or Surveillance E, and End Results Program): National Institutes of Health \u2013 National Cancer Institute: SEER. Cancer Stat Facts: Ovarian Cancer, 2020"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01934"},{"key":"e_1_3_8_5_2","article-title":"ASCO global guidelines: Methods and opportunities","author":"Aziz Z","unstructured":"Aziz Z, Temin S, Bachmann S, et al: ASCO global guidelines: Methods and opportunities. JCO Glob Oncol 10.1200\/GO-24-00310","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.4.513"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31821bb8aa"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00542"},{"key":"e_1_3_8_9_2","first-page":"02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"19","author":"Konstantinopoulos PA","year":"2020","unstructured":"Konstantinopoulos PA, Norquist B, Lacchetti C, et al: Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 19:02960, 2020","journal-title":"J Clin Oncol"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000858"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","unstructured":"Gaitskell K Rogozi\u0144ska E Platt S et al: Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev 10.1002\/14651858.CD007930.pub3","DOI":"10.1002\/14651858.CD007930.pub3"},{"issue":"7","key":"e_1_3_8_13_2","article-title":"Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer","volume":"2023","author":"Newhouse R","year":"2023","unstructured":"Newhouse R, Nelissen E, El-Shakankery KH, et al: Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev 2023(7), 2023","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","unstructured":"Patel A Kalachand R Busschots S et al: Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 10.1002\/14651858.CD008766.pub3","DOI":"10.1002\/14651858.CD008766.pub3"},{"key":"e_1_3_8_15_2","first-page":"Cd007927","article-title":"Epidermal growth factor receptor blockers for the treatment of ovarian cancer","volume":"10","author":"Morrison J","year":"2018","unstructured":"Morrison J, Thoma C, Goodall RJ, et al: Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Cochrane Database Syst Rev 10:Cd007927, 2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.08.075"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.11.026"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01471-5"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.7519"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.307"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-3"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.08.004"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30142-X"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30637-9"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30279-6"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00529"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.1258"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4037"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.12.043"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103294"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00605"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4157-9"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902626"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00531-X"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00006-1"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.017"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2025-0157-CP"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6606"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S38204"},{"key":"e_1_3_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01040-2"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02624"},{"key":"e_1_3_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00462-9"},{"key":"e_1_3_8_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6735"},{"key":"e_1_3_8_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15185"},{"key":"e_1_3_8_48_2","first-page":"2303","article-title":"Efficacy of bevacizumab combined with albumin-bound paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer","volume":"24","author":"Liu B","year":"2019","unstructured":"Liu B, An R, Yu J: Efficacy of bevacizumab combined with albumin-bound paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer. J Buon 24:2303-2309, 2019","journal-title":"J Buon"},{"key":"e_1_3_8_49_2","doi-asserted-by":"publisher","unstructured":"Zachou G El-Khouly F Dilley J: Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev 10.1002\/14651858.CD006119.pub4","DOI":"10.1002\/14651858.CD006119.pub4"},{"key":"e_1_3_8_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61268-8"},{"key":"e_1_3_8_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000877"},{"key":"e_1_3_8_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010602"},{"key":"e_1_3_8_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.02.005"},{"key":"e_1_3_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.03.022"},{"key":"e_1_3_8_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002885"},{"key":"e_1_3_8_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003506"},{"key":"e_1_3_8_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00716"},{"key":"e_1_3_8_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"key":"e_1_3_8_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8995"},{"key":"e_1_3_8_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01357"},{"key":"e_1_3_8_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00541"},{"key":"e_1_3_8_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00857"},{"key":"e_1_3_8_63_2","unstructured":"FDA: FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian Fallopian tube or primary peritoneal carcinoma 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or"},{"key":"e_1_3_8_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.049"},{"key":"e_1_3_8_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.12.002"},{"key":"e_1_3_8_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02175-9"},{"key":"e_1_3_8_67_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01164"},{"key":"e_1_3_8_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00112"},{"key":"e_1_3_8_69_2","unstructured":"A phase 3 randomized open-label study of combination therapy with avutometinib plus defactinib versus investigator's choice of treatment in patients with recurrent low-grade serous ovarian cancer (LGSOC) (RAMP 301). ClinicalTrials.gov identifier: NCT06072781. Updated 2026-04-02. https:\/\/clinicaltrials.gov\/study\/NCT06072781 2026"},{"key":"e_1_3_8_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2022.100942"},{"key":"e_1_3_8_71_2","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2021.138"},{"key":"e_1_3_8_72_2","doi-asserted-by":"publisher","unstructured":"Pappa C Galaal K Smyth S et al: Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 10.1002\/14651858.CD015297","DOI":"10.1002\/14651858.CD015297"},{"key":"e_1_3_8_73_2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e22"},{"key":"e_1_3_8_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_8_75_2","unstructured":"A Phase 3 Open-label multicenter randomized trial of trastuzumab deruxtecan with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in HER2-expressing ovarian cancer (DESTINY-Ovarian01\/ENGOT-ov89\/GEICO144- O\/GOG-3112\/APGOT-OV13). ClinicalTrials.gov identifier: NCT06819007. Updated 2026-03-05 2026. https:\/\/clinicaltrials.gov\/study\/NCT06819007"},{"key":"e_1_3_8_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28940"},{"key":"e_1_3_8_77_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000892"},{"key":"e_1_3_8_78_2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e63"},{"key":"e_1_3_8_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-00118"},{"key":"e_1_3_8_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00626"},{"key":"e_1_3_8_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.07.035"},{"key":"e_1_3_8_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.013"},{"key":"e_1_3_8_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00174"},{"key":"e_1_3_8_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)30409-0"},{"key":"e_1_3_8_85_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.025288"},{"key":"e_1_3_8_86_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_350175"},{"key":"e_1_3_8_87_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6706"},{"key":"e_1_3_8_88_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2518"},{"key":"e_1_3_8_89_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000316"},{"key":"e_1_3_8_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"e_1_3_8_91_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.1183"},{"key":"e_1_3_8_92_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00933"},{"key":"e_1_3_8_93_2","volume-title":"GRADE Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach","author":"Sch\u00fcnemann H","year":"2013","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, et al: GRADE Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. The GRADE Working Group, 2013"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-26-01591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:59:32Z","timestamp":1790632772000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-26-01591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":92,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2026,10,1]]}},"alternative-id":["10.1200\/JCO-26-01591"],"URL":"https:\/\/doi.org\/10.1200\/jco-26-01591","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1200\/GDL.26.0824","asserted-by":"subject"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"2026-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}